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BACKGROUND: Little is known about the risk of colorectal cancer among patients with irritable bowel syndrome (IBS).
METHODS: We conducted a nationwide cohort study using data from the Danish National Registry of Patients and the Danish Cancer
Registry from 1977 to 2008. We included patients with a first-time hospital contact for IBS and followed them for colorectal cancer.
We estimated the expected number of cancers by applying national rates and we computed standardised incidence ratios (SIRs) by
comparing the observed number of colorectal cancers with the expected number. We stratified the SIRs according to age, gender,
and time of follow-up.
RESULTS: Among 57851 IBS patients, we identified 407 cases of colon cancer during a combined follow-up of 506930 years (SIR, 1.14
(95% confidence interval (CI): 1.03–1.25) and 115 cases of rectal cancer, corresponding to a SIR of 0.67 (95% CI: 0.52–0.85). In the
first 3 months after an IBS diagnosis, the SIR was 8.42 (95% CI: 6.48–10.75) for colon cancer and 4.81 (95% CI: 2.85–7.60) for
rectal cancer. Thereafter, the SIRs declined and 4–10 years after an IBS diagnosis, the SIRs for both colon and rectal cancer remained
below 0.95.
CONCLUSION: We found a decreased risk of colorectal cancer in the period 1–10 years after an IBS diagnosis. However, in the first 3
months after an IBS diagnosis, the risk of colon cancer was more than eight-fold increased and the risk of rectal cancer was five-fold
increased. These increased risks are likely to be explained by diagnostic confusion because of overlapping symptomatology.
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Irritable bowel syndrome (IBS) is the most common functional
disorder of the gastrointestinal tract, characterised by abdominal
pain, discomfort, and changes in bowel habits in the absence of
known structural or biochemical abnormalities (Thompson et al,
2000). The prevalence of IBS in western countries ranges between
5–26%, depending on the criteria used to define the disease
(Drossman et al, 1997; Hillila and Farkkila, 2004; Yale et al, 2008)
and it is associated with repeated medical care visits and high costs
(Sandler et al, 2002). Although a primary concern of IBS patients is
their potential risk of developing colorectal cancer (Rey and Talley,
2009), few studies have evaluated the long-term course of IBS
(Svendsen et al, 1985; Harvey et al, 1987; Owens et al, 1995; Garcia
Rodriguez et al, 2000). In a follow-up study of 2956 IBS patients
and 20000 randomly sampled persons from the United Kingdom
General Practitioners Database, with a mean follow-up time of 36
months, the relative risk (RR) of colorectal cancer was 5.8 (95%
confidence interval (CI): 3.0–11.3) (Garcia Rodriguez et al, 2000).
However, after excluding the first year of follow-up, the authors
found that the RR was close to that of the general population
(although no estimates were presented), arguing against a causal
association.
As IBS is such a common condition, any associated increased
risk of colorectal cancer is a public health concern. We therefore
conducted a large nationwide follow-up study to examine the long-
term risk of colon cancer among patients with a hospital diagnosis
of IBS.
PATIENTS AND METHODS
We conducted this nationwide study in Denmark within its
population of 5.4 million habitants in 1977–2008. All Danish
residents have a civil registration number, which is a unique
personal identifier assigned at birth or upon immigration. This
number is included in all public registries and allows unambiguous
linkage between registries. The National Health Service provides
tax-supported health care for all inhabitants of Denmark,
guaranteeing free access to hospitals and general practitioners.
We identified all patients with a hospital contact (either
admission or contact with a hospital-based outpatient clinic) for
IBS using the Danish National Registry of Patients (DNRP), which
has maintained records on all hospital admissions in Denmark
since 1977. Visits to hospital-based outpatient clinics have been
included since 1995. DNRP data includes civil registration number
and up to 20 diagnoses, classified according to the International
Classification of Diseases, eighth revision (ICD-8) until the end of
1993 and tenth revision (ICD-10) thereafter. We used the following
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ycodes to identify IBS: 564.19 in ICD-8, and K 58.0 and K 58.9
in ICD-10 and we defined date of diagnosis as the date of the
first recorded hospital contact in the DNRP. To examine how
colonoscopic surveillance affects long-term risk of colorectal
cancer, we also identified patients who underwent colonoscopy
or flexible sigmoidoscopy within 3 months before or after their
first recorded IBS diagnosis, based on Nordic Classification of
Surgical Procedures codes KUJF32-45. These codes have been
included in the DNRP since the end of 1995.
Linkage to the Danish Cancer Registry allowed us to identify
cancers diagnosed in patients with IBS. This is a population-based
nationwide registry containing data on incident cases of cancer in
Denmark since 1943 (Storm et al, 1997). Data recorded for each
individual include civil registration number, method of cancer
verification, stage, and residence on the date of cancer diagnosis.
Diagnoses in the Cancer Registry have been coded according to
ICD-10 since 2004. During the 1978–2003 period, all data were
initially coded according to ICD-7; subsequently they were recoded
using the ICD-10 classification. We used ICD-10 codes C18-C19
to identify cases of colon cancer and C20 to identify cases of rectal
cancer. Patients with a cancer diagnosis before the date of their
first IBS diagnosis were not included.
The civil registration number encodes age and gender. We
computed age at the time of IBS diagnosis and categorised it into
seven groups (o20 years, 20–39 years, 40–49 years, 50–59 years,
60–69 years, 70–79 years, and 80þ years).
Statistical analyses
Follow-up started on the date of the first IBS-related hospital
contact and continued until the date of a colorectal cancer
diagnosis, the date of another cancer diagnosis, the date of death,
the date of migration, or 31 December 2008, whichever came first.
To compute standardised incidence ratios (SIRs) as a measure of
relative risk, we estimated the expected number of cancers in our
IBS population by applying rates from the Danish Cancer Registry
(standardised on age, gender, and calendar time in 1-year
intervals) to person-years of observation. We then compared the
observed number of cases to the expected number and calculated
a 95% CI, assuming that the observed number of cancers in
a specific category followed a Poisson distribution. We computed
SIRs for colorectal cancer overall and for colon and rectal
cancer separately for the following follow-up periods: 0–91 days,
92–365 days, 366 days to 3 years, 43–5 years, 45–10 years,
and 410 years. We stratified the analyses according to gender and
age group. As colonoscopy enables detection and removal of
precancerous lesions, we expected the risk of colorectal cancer to
be reduced by this procedure (Brenner et al, 2010). We therefore
conducted an analysis restricted to IBS patients with a recorded
colonoscopy or flexible sigmoidoscopy. Since the DNRP was
established in 1977, our estimates could be biased because of
left-truncation of the data; we therefore conducted a subanalysis
based on patients with a first IBS diagnosis in 1980–2008 and no
IBS diagnosis in 1977–1979. We also conducted separate analysis
for the two periods 1977–1994 and 1995–2008. We used SAS,
version 9.1 (SAS Inc., Cary, NC, USA) for all analyses.
RESULTS
We identified 57851 patients (39998 women and 17853 men) with
a first-time IBS-related hospital contact. Of these, 44% were
diagnosed as inpatients and 56% were diagnosed during a
hospital-based outpatient visit. Median age at diagnosis was
47 years (interquartile range: 32–62 years).
During a combined follow-up of 506930 years, we observed 522
cases of colorectal cancer with 530 expected, corresponding to a
SIR of 0.99 (95% CI: 0.90–1.07). Within 3 months of IBS diagnosis,
the SIR for colorectal cancer was 7.23 (95% CI: 5.75–8.97). In the
period, 4 months to 1 year after IBS diagnosis, the SIR was
1.41 (95% CI: 1.04–1.87). The SIRs decreased to 0.89 (95% CI:
0.70–1.11) for the second and third years of follow up, 0.79
(95% CI: 0.61–1.02) for the fourth and fifth years of follow-up, 0.74
(95% CI: 0.60–0.89) for the sixth to the 10 years of follow up, and
0.83 (95% CI: 0.71–0.98) for those with more than 10 years of
follow-up.
Among the 522 cancers, we identified 407 cases of colon cancer,
including rectosigmoid cancer. This yielded a SIR of 1.14 (95% CI:
1.03–1.25) (Table 1). The SIR was 1.00 (95% CI: 0.81–1.21) for
men and 1.19 (95% CI: 1.06–1.34) for women. Within 3 months
of IBS diagnosis, the SIR for colon cancer was 8.42 (95% CI:
6.48–10.75). In the second and third years of follow-up, the SIR
for colon cancer decreased to 1.08 (95% CI: 0.83–1.39). In the
fourth and following years after IBS diagnosis, we consistently
observed SIRs below 0.95 (Table 1).
We also identified 115 cases of rectal cancer among IBS patients
during the study period, corresponding to a SIR of 0.67 (95% CI:
0.52–0.85) (Table 2). Within 3 months of IBS diagnosis, the SIR
for rectal cancer was 4.81 (95% CI: 2.85–7.60), and in the second
and third years of follow-up, the SIR for rectal cancer decreased to
0.50 (95% CI: 0.27–0.83), and after more than 10 years the SIR was
0.61 (95% CI: 0.42–0.85).
We identified 19150 IBS patients diagnosed after 1995 who had
undergone colonoscopy or flexible sigmoidoscopy within 3 months
before or after the date of IBS diagnosis. Overall, the SIR of colon
cancer in this group was 1.03 (95% CI: 0.78–1.34). However, after
stratifying by follow-up period, we found that an increased risk of
colon cancer was confined to the first 3 months following IBS
diagnosis (SIR, 10.77 (95% CI: 7.03–15.78)) (Table 1). For rectal
cancer, the SIR for the first 3 months following IBS diagnosis was
10.86 (95% CI: 5.78–18.58). After 4–12 months of follow-up, the
SIR decreased to 1.13 (95% CI: 0.31–2.90). In the following years,
the SIRs all suggested a protective effect of colonoscopy or flexible
sigmoidoscopy (Table 2).
Table 3 shows observed and expected numbers of colon and
rectal cancers, and corresponding SIRs for patients diagnosed in
1977–1994 and 1995–2008, separately. In 1995–2008, an increased
risk of colon cancer was observed only in the first 3 months after
IBS diagnosis. In 1977–1994, the risk was increased in the first 3
years after IBS diagnosis. For rectal cancer, the increased risk was
only observed in the period 1995–2008 and the risk was confined
to the first 3 months.
When we analysed data based on patients diagnosed with IBS
in 1980–2008, we found only minor differences in our estimates
(data not shown).
DISCUSSION
In this cohort study of nearly 60000 IBS patients, we found no
evidence of increased risk of colorectal cancer in the period
starting 1 year after diagnosis. However, in the first 3 months after
an IBS diagnosis, we found a more than eight-fold increased rate of
colon cancer and a nearly five-fold increased rate of rectal cancer.
In the following years, there was a lower risk of both colon and
rectal cancer. If IBS was a cause of colorectal cancer, we would
have expected the risk to increase with length of follow-up, because
of these cancers’ long latency period. If, alternatively, IBS and
colorectal cancer had common risk factors, a continued excess risk
over time also would be expected. Our findings thus suggest that
symptoms of colorectal cancer may initially be misinterpreted as
IBS and then the associated clinical examinations subsequently
lead to the diagnosis of colorectal cancer. In IBS patients without
an early diagnosis of colorectal cancer, the risk remained lower
than expected for at least 10 years. For rectal cancer, we even
observed an overall 30% decreased risk in patients diagnosed
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ywith IBS, suggesting that rectal cancer is ruled out before an IBS
diagnosis is given. We did not have information on colonoscopy for
all our IBS patients, but when we restricted our analysis to those
with a known colonoscopy or flexible sigmoidoscopy at the time of
IBS diagnosis, the decreased long-term risk was even clearer.
Our findings are consistent with a study based on the UK
General Practice Research Database (Garcia Rodriguez et al, 2000),
which also found a nearly six-fold increased risk of colorectal
cancer mainly confined to the first year after an IBS diagnosis.
Our longer follow-up and larger sample size allowed us to extend
Table 1 Observed and expected numbers of colon cancers, including rectosigmoid cancers, and corresponding standardised incidence ratios in patients
with irritable bowel syndrome overall and by period of follow-up, gender, age at diagnosis, and calendar period of diagnosis









cancers, N SIR (95% CI)
Total 407 358.6 1.14 (1.03–1.25) 56 54.3 1.03 (0.78–1.34)
Follow-up
p3 months 64 7.6 8.42 (6.48–10.75) 26 2.4 10.77 (7.03–15.78)
4–12 months 34 22.8 1.49 (1.03–2.08) 3 7.1 0.42 (0.09–1.24)
2nd and 3rd year 62 57.4 1.08 (0.83–1.39) 9 16.6 0.54 (0.25–1.03)
4th and 5th year 41 50.8 0.81 (0.58–1.10) 7 12.5 0.56 (0.22–1.15)
6th to 10th year 89 95.3 0.93 (0.75–1.15) 11 14.1 0.78 (0.39–1.39)
410 years 117 124.7 0.94 (0.78–1.12) 0 1.6 —
Gender
Women 302 253.1 1.19 (1.06–1.34) 34 35.0 0.97 (0.67–1.36)
Men 105 105.5 1.00 (0.81–1.21) 22 19.3 1.14 (0.71–1.73)
Age
o20 years 0 0.3 — 0
20–39 years 25 16.5 1.52 (0.98–2.24) 5 0.9 5.47 (1.77–12.75)
40–49 years 43 36.7 1.17 (0.85–1.58) 1 3.2 0.31 (0.01–1.73)
50–59 years 88 78.5 1.12 (0.90–1.38) 12 10.7 1.12 (0.58–1.95)
60–69 years 113 107.5 1.05 (0.87–1.26) 13 17.4 0.75 (0.40–1.28)
70–79 years 96 91.3 1.05 (0.85–1.28) 18 16.3 1.10 (0.65–1.74)
X80 years 42 27.8 1.51 (1.09–2.04) 7 5.7 1.23 (0.49–2.53)
Abbreviations: IBS¼irritable bowel syndrome; CI¼confidence interval; SIR¼standardised incidence ratio.
aColonoscopy or flexible sigmoidoscopy.
Table 2 Observed and expected number of rectal cancers and corresponding standardised incidence ratios in patients with irritable bowel syndrome
overall and according to period of follow-up, gender, age at diagnosis and calendar period of diagnosis









cancers, N SIR (95% CI)
Total 115 171.0 0.67 (0.52–0.85) 27 27.3 0.99 (0.65–1.44)
Follow-up
p3 months 18 3.7 4.81 (2.85–7.60) 13 1.2 10.86 (5.78–18.58)
4–12 months 14 11.2 1.25 (0.68–2.09) 4 3.5 1.13 (0.31–2.90)
2nd and 3rd year 14 28.2 0.50 (0.27–0.83) 3 8.3 0.36 (0.07–1.05)
4th and 5th year 19 24.7 0.77 (0.46–1.20) 4 6.3 0.63 (0.17–1.62)
6th to 10th year 15 45.6 0.33 (0.18–0.54) 3 7.1 0.42 (0.09–1.23)
410 years 35 57.5 0.61 (0.42–0.85) 0 0.8 —
Gender
Women 71 102.7 0.69 (0.54–0.87) 12 14.6 0.82 (0.43–1.44)
Men 44 68.3 0.64 (0.47–0.86) 15 12.8 1.17 (0.66–1.94)
Age
o20 years 0 0.2 — 0 0 —
20–39 years 6 9.6 0.62 (0.23–1.36) 1 0.5 1.85 (0.05–10.32)
40–49 years 14 20.7 0.68 (0.37–1.13) 3 2.1 1.40 (0.29–4.08)
50–59 years 26 41.9 0.62 (0.40–0.91) 2 6.8 0.29 (0.04–1.06)
60–69 years 30 50.2 0.60 (0.40–0.85) 13 9.0 1.45 (0.77–2.48)
70–79 years 24 37.6 0.64 (0.41–0.95) 3 6.7 0.45 (0.09–1.31)
X80 years 15 10.9 1.38 (0.77–2.28) 5 2.2 2.30 (0.75–5.36)
Abbreviations: IBS¼irritable bowel syndrome; CI¼confidence interval; SIR¼standardised incidence ratio.
aColonoscopy or flexible sigmoidoscopy.
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ythese findings by showing a compensatory decreased risk in the
second and following years after an IBS diagnosis. Although IBS is
diagnosed according to symptom-based diagnostic criteria, use of
routine sigmoidoscopy has been recommended by some experts
(Camilleri and Prather, 1992; American Gastroenterological
Association, 1997). In a multicenter randomised trial, Atkin et al
(2010) demonstrated that once-only flexible sigmoidoscopy (during
which polyps were removed) was associated with an IRR of
colorectal cancer of 0.77 (95% CI: 0.70–0.84) during a median
follow up of 11.2 years, compared with controls who did not undergo
sigmoidoscopy. Brenner et al (2010) showed that the prevalence of
left-sided colorectal neoplasms was clearly reduced within a 10-year
period after colonoscopy; we found a similar effect in IBS patients.
Access to the Danish Cancer Registry allowed us to conduct a
cohort study in a population-based setting with virtually complete
follow-up of cancer cases. However, our data on IBS were based on
diagnoses registered in the DNRP and it is known that these are
not entirely accurate. Moreover, IBS has been defined differently
over time, changing the clinical characteristics used to diagnose
the disease. Thus, use of the Rome criteria results in a considerably
lower prevalence of IBS compared with use of the Manning criteria
(Boyce et al, 2006). Such diagnostic differences may explain the
slightly higher risk of colon cancer among patients diagnosed in
the first part of our study period. Since the DNRP was established
in 1977, patients diagnosed with IBS in the first part of our study
period may have been prevalent cases and not newly diagnosed
cases. Changing our study period to 1980–2008 did not, however,
change the results substantially – so any bias caused by left-truncated
data is probably minor. Our use of routine data also may be a
strength, as the study itself did not affect the process of diagnosing
IBS. At the same time, IBS and colorectal cancer share symptoms,
and the first symptoms of colorectal cancer may easily be confused
with IBS. The increased risks of both colon and rectal cancers in the
first year after the IBS diagnosis are thus likely to be explained by an
incorrect IBS diagnosis (Garcia Rodriguez et al, 2000).
The restriction of our study to IBS patients diagnosed in a
hospital contact may have produced some bias. Nevertheless, IBS
patients without any hospital contacts should not be at higher risk
of developing colon cancer than patients included in our study. In
contrast, patients referred for evaluation in a hospital setting are
likely to have a higher risk of colorectal cancer than those without
hospital contacts if the referral reflects a higher level of concern
about colorectal cancer. We therefore expect that such bias caused
us to overestimate the risk. Restriction to patients diagnosed in
1995–2008 after inclusion of outpatient visits in the DNRP did not
change our conclusions.
In conclusion, our study does not support the hypothesis that
IBS is associated with an elevated risk of colorectal cancer. The
increased risk of colorectal cancer in the first year after the IBS
diagnosis is likely to be because of diagnostic confusion because of
overlapping symptomatology between the two diseases.
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